Purpose: Labial mucosa transplantation for the treatment of canine keratoconjunctivitis sicca (KCS) has been reported recently. Postoperative alleviation of clinical signs was noted and assumed to be the result of labial salivary glands providing lubrication to the ocular tissue. The aim of this...

Background: Canine keratoconjunctivitis sicca (KCS) is predominantly an immune-mediated disease. Current therapy of canine KCS is mainly by immunosuppressant, but the effectiveness was limited in some patients. In the past few years, some studies showed the results of the use of mesenchymal stem...

This was realized to elucidate the forms of treatment of keratoconjunctivitis sicca (KCS) in dogs with minimally invasive methods, using only topical drugs such as lachrymimetics, lacrimomimetics, mucolytics, immunosuppressants and antibacterials. Considering that KCS is a common chronic...

Objective: To assess the clinical safety and efficacy of adjunctive therapy using Vizoovet to ameliorate clinical signs of keratoconjunctivitis sicca (KCS) in dogs. Animals studied: Twenty client-owned dogs. Procedures: Canine patients diagnosed with KCS were enrolled in this prospective study....

There is little peer-reviewed research assessing therapeutic effectiveness in canine eye disease. Current treatments used in first opinion and ophthalmology referral practices are also somewhat poorly documented. The aim of this study was to investigate the current management of canine ...

This article discusses the aetiological factors, classification, clinical aspects, and diagnosis of canine keratoconjunctivitis sicca; and highlights the advances in the medical treatment and management of canine keratoconjunctivitis sicca.

Interferons (IFNs) are cytokines that play an important role in the immune response of animals and humans. A number of studies reviewed here have evaluated the use of human, canine and feline IFNs as treatments for infectious, inflammatory and neoplastic disease in dogs and cats. Recombinant canine ...

Objective: To assess the efficacy of 0.1% oclacitinib as a single agent, and in combination with tacrolimus 0.01%, for the control of ophthalmic signs of keratoconjunctivitis sicca (KCS) in dogs. Animals studied: Thirty-two dogs (57 eyes) diagnosed with idiopathic KCS were included. Inclusion...

Purpose: To evaluate the effect of twice daily aqueous 0.02% sirolimus drops on tear production in normal dogs and dogs with refractory keratoconjunctivitis sicca (KCS). Methods: Two groups of dogs were studied. Ten normal dogs with no signs of ocular disease were administered topical 0.02%...

Objective: To evaluate repeatability and reproducibility of tear osmolarity measured using the TearLab^TM osmometer in normal dogs and to assess its diagnostic potential in dogs with keratoconjunctivitis sicca (KCS). Animals studied: Beagle dogs; six normal and five with KCS. Procedures: Tear...